Poseida Therapeutics, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Poseida Therapeutics, Inc. | PSTX - NASDAQ |
$16.00-$16.00 | $16.00 | $17.00 | 14 million | 7/10/2020 |
| BofA Securities, Piper Sandler, William Blair | ||||||
Co-Manager(s): | ||||||
| Health Care | ||||||
Filing(s): Filed 2019-01-04 Updated Prospectus 2020-06-19 Terms Added 2020-07-06 Terms Changed 2020-07-09 | ||||||
Poseida Therapeutics, Inc. Quote & Chart - Click for current quote - PSTX
IPO Boutique aggregates information on public companies and private companies, such as "PSTX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Poseida Therapeutics, Inc. (adapted from Poseida Therapeutics, Inc. prospectus):
They are a clinical-stage biopharmaceutical company focused on leveraging their proprietary next-generation, non-viral gene engineering technologies to create life-saving therapeutics for patients with high unmet medical need.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage biopharmaceutical company focused on leveraging their proprietary next-generation, non-viral gene engineering technologies to create life-saving therapeutics for patients with high unmet medical need.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "PSTX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.